Recently approved drugs for the treatment of multiple myeloma

Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR provides an overview of the drugs recently approved for the treatment multiple myeloma (MM), and for which the data has been presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. These include daratumumab, an anti-CD38 monoclonal antibody; ixazomib, the first oral proteasome inhibitor; and elotuzumab, a monoclonal antibody targeting signalling lymphocytic activation molecule F7 (SLAMF7).